Thus, targeting the interface between MuRF1 and the E2(s) specifically involved in the degradation of contractile proteins rather than individual enzymes, may represent attractive therapeutic strategies to fight against muscle atrophy. This evidence concerns the gene TRIM63 and muscle atrophy.